JP2011520098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520098A5 JP2011520098A5 JP2011505224A JP2011505224A JP2011520098A5 JP 2011520098 A5 JP2011520098 A5 JP 2011520098A5 JP 2011505224 A JP2011505224 A JP 2011505224A JP 2011505224 A JP2011505224 A JP 2011505224A JP 2011520098 A5 JP2011520098 A5 JP 2011520098A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- macers
- time point
- level
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 34
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 19
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 19
- 239000000692 natriuretic peptide Substances 0.000 claims description 19
- 230000002411 adverse Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 2
- 102400001263 NT-proBNP Human genes 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 102000046255 Type III Sodium-Phosphate Cotransporter Proteins Human genes 0.000 claims description 2
- 108091006286 Type III sodium-phosphate co-transporters Proteins 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 231100000225 lethality Toxicity 0.000 claims description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 235000009421 Myristica fragrans Nutrition 0.000 claims 2
- 239000001115 mace Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4615808P | 2008-04-18 | 2008-04-18 | |
| US61/046,158 | 2008-04-18 | ||
| PCT/US2009/040941 WO2009129454A2 (en) | 2008-04-18 | 2009-04-17 | Predicting risk of major adverse cardiac events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014082442A Division JP5873521B2 (ja) | 2008-04-18 | 2014-04-14 | 主要有害心イベントのリスクを予測する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520098A JP2011520098A (ja) | 2011-07-14 |
| JP2011520098A5 true JP2011520098A5 (enExample) | 2012-12-27 |
| JP5526122B2 JP5526122B2 (ja) | 2014-06-18 |
Family
ID=41199760
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505224A Expired - Fee Related JP5526122B2 (ja) | 2008-04-18 | 2009-04-17 | 主要有害心イベントのリスクを予測する方法 |
| JP2014082442A Expired - Fee Related JP5873521B2 (ja) | 2008-04-18 | 2014-04-14 | 主要有害心イベントのリスクを予測する方法 |
| JP2016006007A Expired - Fee Related JP6200975B2 (ja) | 2008-04-18 | 2016-01-15 | 主要有害心イベントのリスクを予測する方法 |
| JP2017162932A Expired - Fee Related JP6484679B2 (ja) | 2008-04-18 | 2017-08-28 | 主要有害心イベントのリスクを予測する方法 |
| JP2019026401A Expired - Fee Related JP6788050B2 (ja) | 2008-04-18 | 2019-02-18 | 主要有害心イベントのリスクを予測する方法 |
| JP2020181010A Ceased JP2021039108A (ja) | 2008-04-18 | 2020-10-29 | 主要有害心イベントのリスクを予測する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014082442A Expired - Fee Related JP5873521B2 (ja) | 2008-04-18 | 2014-04-14 | 主要有害心イベントのリスクを予測する方法 |
| JP2016006007A Expired - Fee Related JP6200975B2 (ja) | 2008-04-18 | 2016-01-15 | 主要有害心イベントのリスクを予測する方法 |
| JP2017162932A Expired - Fee Related JP6484679B2 (ja) | 2008-04-18 | 2017-08-28 | 主要有害心イベントのリスクを予測する方法 |
| JP2019026401A Expired - Fee Related JP6788050B2 (ja) | 2008-04-18 | 2019-02-18 | 主要有害心イベントのリスクを予測する方法 |
| JP2020181010A Ceased JP2021039108A (ja) | 2008-04-18 | 2020-10-29 | 主要有害心イベントのリスクを予測する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8090562B2 (enExample) |
| EP (5) | EP2660599B1 (enExample) |
| JP (6) | JP5526122B2 (enExample) |
| AU (3) | AU2009236109B2 (enExample) |
| CA (1) | CA2720674A1 (enExample) |
| DK (4) | DK2660599T3 (enExample) |
| ES (4) | ES2590213T3 (enExample) |
| HR (2) | HRP20131100T1 (enExample) |
| HU (2) | HUE039963T2 (enExample) |
| PL (4) | PL2660599T3 (enExample) |
| PT (4) | PT2660599E (enExample) |
| SI (4) | SI2269063T1 (enExample) |
| WO (1) | WO2009129454A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| PT3072978T (pt) | 2002-05-09 | 2018-10-15 | Brigham & Womens Hospital Inc | 1l1rl-1 como um marcador de doença cardiovascular |
| ES2529618T3 (es) | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves |
| EP2021799B1 (en) * | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| ES2566169T3 (es) | 2006-05-01 | 2016-04-11 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedad cardiovascular |
| HUE025058T2 (en) * | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
| US9968266B2 (en) | 2006-12-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Risk stratification based heart failure detection algorithm |
| DK2660599T3 (en) | 2008-04-18 | 2014-12-08 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
| JP5711131B2 (ja) * | 2008-10-07 | 2015-04-30 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 最初の有害事象の予測のためのバイオマーカー |
| US9561006B2 (en) * | 2008-10-15 | 2017-02-07 | The United States Of America As Represented By The Secretary Of The Navy | Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival |
| US8417541B1 (en) * | 2009-08-27 | 2013-04-09 | Cerner Innovation, Inc. | Multi-stage model for predicting probabilities of mortality in adult critically ill patients |
| JP5730879B2 (ja) * | 2009-09-25 | 2015-06-10 | ヴォルケイノウ・コーポレーション | 確認された生理学的パラメータに基づいて患者が臨床事象または臨床的無症状事象を有する可能性を決定するデバイスおよびシステム |
| ES2859577T3 (es) | 2010-04-09 | 2021-10-04 | Critical Care Diagnostics Inc | Anticuerpos contra ST-2 humana soluble y ensayos |
| US10943676B2 (en) | 2010-06-08 | 2021-03-09 | Cerner Innovation, Inc. | Healthcare information technology system for predicting or preventing readmissions |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| CA2842072A1 (en) | 2011-07-18 | 2013-01-24 | James V. Snider | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| HK1208624A1 (en) | 2012-05-18 | 2016-03-11 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| CN102830234A (zh) * | 2012-08-10 | 2012-12-19 | 杭州华得森生物技术有限公司 | 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒 |
| SG10201704311VA (en) | 2012-08-16 | 2017-07-28 | Critical Care Diagnostics Inc | Methods for predicting risk of developing hypertension |
| HK1212057A1 (en) * | 2012-08-21 | 2016-06-03 | 重症监护诊断股份有限公司 | Multimarker risk stratification |
| RU2510505C1 (ru) * | 2012-11-15 | 2014-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда |
| GB201310290D0 (en) * | 2013-06-10 | 2013-07-24 | Univ Manchester | Method for determining a probability of a major adverse cardiac event (MACE) |
| MX2016009060A (es) * | 2014-01-10 | 2016-09-09 | Critical Care Diagnostics Inc | Metodos y sistemas para determinar el riesgo de falla cardiaca. |
| KR102328327B1 (ko) | 2014-09-26 | 2021-11-22 | 소마로직, 인크. | 심혈관 위험 사건 예측 및 이의 용도 |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| WO2016140958A1 (en) * | 2015-03-02 | 2016-09-09 | Estes Edward Harvey | Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score |
| CN109152529B (zh) * | 2016-04-01 | 2021-10-22 | 心脏起搏器股份公司 | 多疾病患者管理 |
| AT518560B1 (de) * | 2016-04-18 | 2018-01-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegebalken für eine Schwenkbiegemaschine |
| US11615891B2 (en) | 2017-04-29 | 2023-03-28 | Cardiac Pacemakers, Inc. | Heart failure event rate assessment |
| US20200074313A1 (en) * | 2018-08-29 | 2020-03-05 | Koninklijke Philips N.V. | Determining features to be included in a risk assessment instrument |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| WO2020236670A1 (en) | 2019-05-17 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| US11551817B2 (en) | 2020-01-14 | 2023-01-10 | International Business Machines Corporation | Assessing unreliability of clinical risk prediction |
| WO2022189445A1 (en) * | 2021-03-08 | 2022-09-15 | Sanofi | Cardiovascular disease |
| WO2023086746A1 (en) * | 2021-11-11 | 2023-05-19 | Beckman Coulter, Inc. | Assessment of risk for major adverse cardiac event |
| US12553310B2 (en) | 2023-09-07 | 2026-02-17 | Halliburton Energy Services, Inc. | Fire on demand barrier valve using wireless signal transmission and spring-forced piston |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
| US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
| JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体 |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| JP2732005B2 (ja) | 1992-12-14 | 1998-03-25 | 眞一 富永 | ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法 |
| JPH0731479A (ja) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法 |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| EP0963205A4 (en) | 1996-08-23 | 2002-10-02 | Human Genome Sciences Inc | T1 RECEPTOR-LIGAND II |
| AU6181498A (en) | 1997-02-28 | 1998-09-18 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
| DE19711932A1 (de) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms |
| EP2305235A1 (en) | 1997-04-02 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
| EP0988552B1 (en) | 1997-06-10 | 2010-11-24 | Lpath, Inc. | Methods for early detection of heart disease |
| WO1999013331A1 (en) | 1997-09-11 | 1999-03-18 | Shionogi & Co., Ltd. | Immunoassay method for bnp |
| GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| GB9827348D0 (en) * | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
| WO2000035473A2 (en) | 1998-12-18 | 2000-06-22 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
| WO2000073498A1 (en) | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| FR2795823B1 (fr) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
| EP1872797A3 (en) | 1999-08-24 | 2008-04-02 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| FR2807170B1 (fr) | 2000-03-30 | 2002-06-28 | Sipal | Charniere elastique a frottement reduit |
| IL149251A0 (en) | 2000-08-22 | 2002-11-10 | Brigham & Womens Hospital | Diagnosis and treatment of cardiovascular conditions |
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
| FI20010019A7 (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen gastriitin diagnostisoimiseksi |
| US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| JP3806694B2 (ja) | 2001-05-04 | 2006-08-09 | バイオサイト インコーポレイテッド | 急性冠状動脈症候群の診断マーカーおよびその使用方法 |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
| US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
| PT3072978T (pt) | 2002-05-09 | 2018-10-15 | Brigham & Womens Hospital Inc | 1l1rl-1 como um marcador de doença cardiovascular |
| US20040005615A1 (en) | 2002-05-24 | 2004-01-08 | Jing Li | Amplification and overexpression of oncogenes |
| US8263325B2 (en) | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
| WO2004046729A2 (en) * | 2002-11-21 | 2004-06-03 | The University Of Leicester | Bodily fluid markers of tissue hypoxia |
| US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
| US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
| US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| US20060257558A1 (en) | 2003-10-31 | 2006-11-16 | Hiroshi Nomura | Plasma polymerization of atomically modified surfaces |
| CA2921196C (en) | 2003-11-26 | 2019-03-05 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| ATE546734T1 (de) | 2003-12-05 | 2012-03-15 | Cleveland Clinic Foundation | Risikomarker für eine herzkreislaufkrankheit |
| US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| WO2006066095A1 (en) | 2004-12-17 | 2006-06-22 | Clearwater Systems Corporation | Method and apparatus for treating fluids |
| JP4870686B2 (ja) | 2005-01-24 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | 抗炎症剤の投与に関連する心血管リスクを評価するための心臓ホルモンの使用 |
| EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| US20070021977A1 (en) | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
| JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
| ES2529618T3 (es) * | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves |
| EP2021799B1 (en) | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| ES2566169T3 (es) | 2006-05-01 | 2016-04-11 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedad cardiovascular |
| HUE025058T2 (en) | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
| WO2007130627A2 (en) | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
| CA2659082A1 (en) * | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
| WO2008116083A1 (en) | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| WO2008140793A2 (en) | 2007-05-11 | 2008-11-20 | Tufts Medical Center | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
| GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
| US20100267062A1 (en) | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
| FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
| DK2660599T3 (en) | 2008-04-18 | 2014-12-08 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
| WO2010025393A2 (en) * | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
| EP2347266B9 (en) | 2008-11-11 | 2014-02-12 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm |
| EA201290311A1 (ru) | 2009-11-13 | 2012-12-28 | БиДжи МЕДИСИН, ИНК. | Факторы риска и прогнозирование инфаркта миокарда |
| US8258456B2 (en) | 2009-11-27 | 2012-09-04 | Himax Imaging, Inc. | Image sensor |
| ES2859577T3 (es) | 2010-04-09 | 2021-10-04 | Critical Care Diagnostics Inc | Anticuerpos contra ST-2 humana soluble y ensayos |
| RU2017110678A (ru) | 2010-11-01 | 2019-01-24 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
| RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| US8615387B2 (en) * | 2011-04-07 | 2013-12-24 | Invensys Systems, Inc. | Dynamic simulation of fluid filled vessels |
| CA2842072A1 (en) | 2011-07-18 | 2013-01-24 | James V. Snider | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| HK1208624A1 (en) | 2012-05-18 | 2016-03-11 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| SG10201704311VA (en) * | 2012-08-16 | 2017-07-28 | Critical Care Diagnostics Inc | Methods for predicting risk of developing hypertension |
| HK1212057A1 (en) | 2012-08-21 | 2016-06-03 | 重症监护诊断股份有限公司 | Multimarker risk stratification |
| US9665593B2 (en) * | 2013-03-28 | 2017-05-30 | International Business Machines Corporation | Dynamically synching elements in file |
| JP6178687B2 (ja) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | グラビア塗工装置 |
| MX2016009060A (es) | 2014-01-10 | 2016-09-09 | Critical Care Diagnostics Inc | Metodos y sistemas para determinar el riesgo de falla cardiaca. |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
| USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2009
- 2009-04-17 DK DK13179055.2T patent/DK2660599T3/en active
- 2009-04-17 EP EP13179055.2A patent/EP2660599B1/en not_active Not-in-force
- 2009-04-17 ES ES14177846.4T patent/ES2590213T3/es active Active
- 2009-04-17 SI SI200930776T patent/SI2269063T1/sl unknown
- 2009-04-17 US US12/425,956 patent/US8090562B2/en active Active
- 2009-04-17 HU HUE16166093A patent/HUE039963T2/hu unknown
- 2009-04-17 PL PL13179055T patent/PL2660599T3/pl unknown
- 2009-04-17 PT PT131790552T patent/PT2660599E/pt unknown
- 2009-04-17 SI SI200931045T patent/SI2660599T1/sl unknown
- 2009-04-17 PT PT97318422T patent/PT2269063E/pt unknown
- 2009-04-17 CA CA2720674A patent/CA2720674A1/en not_active Abandoned
- 2009-04-17 DK DK16166093.1T patent/DK3093663T3/en active
- 2009-04-17 HR HRP20131100AT patent/HRP20131100T1/hr unknown
- 2009-04-17 HU HUE14177846A patent/HUE029880T2/en unknown
- 2009-04-17 PL PL16166093T patent/PL3093663T3/pl unknown
- 2009-04-17 DK DK09731842.2T patent/DK2269063T3/da active
- 2009-04-17 ES ES16166093.1T patent/ES2687401T3/es active Active
- 2009-04-17 JP JP2011505224A patent/JP5526122B2/ja not_active Expired - Fee Related
- 2009-04-17 PL PL14177846.4T patent/PL2827152T3/pl unknown
- 2009-04-17 DK DK14177846.4T patent/DK2827152T3/en active
- 2009-04-17 PT PT16166093T patent/PT3093663T/pt unknown
- 2009-04-17 EP EP18166387.3A patent/EP3378955A1/en not_active Withdrawn
- 2009-04-17 ES ES09731842.2T patent/ES2443125T3/es active Active
- 2009-04-17 WO PCT/US2009/040941 patent/WO2009129454A2/en not_active Ceased
- 2009-04-17 PT PT141778464T patent/PT2827152T/pt unknown
- 2009-04-17 SI SI200931872T patent/SI3093663T1/sl unknown
- 2009-04-17 EP EP16166093.1A patent/EP3093663B1/en not_active Not-in-force
- 2009-04-17 PL PL09731842T patent/PL2269063T3/pl unknown
- 2009-04-17 ES ES13179055.2T patent/ES2525029T3/es active Active
- 2009-04-17 SI SI200931469A patent/SI2827152T1/sl unknown
- 2009-04-17 EP EP09731842.2A patent/EP2269063B1/en not_active Not-in-force
- 2009-04-17 EP EP14177846.4A patent/EP2827152B1/en not_active Not-in-force
- 2009-04-17 AU AU2009236109A patent/AU2009236109B2/en not_active Ceased
-
2011
- 2011-11-18 US US13/299,612 patent/US20120065897A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/787,137 patent/US9886553B2/en not_active Expired - Fee Related
-
2014
- 2014-04-03 US US14/244,526 patent/US9965593B2/en active Active
- 2014-04-14 JP JP2014082442A patent/JP5873521B2/ja not_active Expired - Fee Related
- 2014-11-03 HR HRP20141056AT patent/HRP20141056T1/hr unknown
-
2016
- 2016-01-15 JP JP2016006007A patent/JP6200975B2/ja not_active Expired - Fee Related
- 2016-02-04 AU AU2016200697A patent/AU2016200697B2/en not_active Ceased
-
2017
- 2017-08-28 JP JP2017162932A patent/JP6484679B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-04 AU AU2018202350A patent/AU2018202350A1/en not_active Abandoned
- 2018-04-12 US US15/951,376 patent/US11170896B2/en active Active
-
2019
- 2019-02-18 JP JP2019026401A patent/JP6788050B2/ja not_active Expired - Fee Related
-
2020
- 2020-10-29 JP JP2020181010A patent/JP2021039108A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6484679B2 (ja) | 主要有害心イベントのリスクを予測する方法 | |
| JP2019105645A5 (enExample) | ||
| JP6757757B2 (ja) | 高血圧症を発症するリスクを予測するための方法 | |
| Adamopoulos et al. | Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy | |
| JP7565291B2 (ja) | 消化管手術を受けた患者のｍａｃｃｅの診断方法 | |
| JP2014514536A5 (enExample) | ||
| CN111500710A (zh) | circRNA730作为生物标志物在预测、诊断或预后脓毒症中的用途 | |
| Hadzibegovic et al. | Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings | |
| Chatzistamatiou et al. | Nocturnal hypertension: poor correlation with office blood pressure but strong prognostic factor for target organ damage | |
| Kievit et al. | Efficient selective screening for heart failure in elderly men and women from the community: A diagnostic individual participant data meta-analysis | |
| Zoltowska et al. | Association between hypothyroidism and takotsubo cardiomyopathy: analysis of nationwide inpatient sample database | |
| Tang et al. | Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation? | |
| Rizzi et al. | Unfavorable donor pretransplant APACHE II, SAPS II, and SOFA scores are not associated with outcome: implications for heart transplant donor selection | |
| Maeder et al. | N-terminal pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea | |
| RU2014107752A (ru) | Среднерегиональный предшественник предсердного натрийуретического пептида (pro-anp) для идентификации пациентов с фибрилляцией предсердий, начавшейся меньше, чем 48 часов тому назад | |
| JP2017534874A5 (enExample) | ||
| Vallejo-Vaz | Novel biomarkers in heart failure beyond natriuretic peptides—the case for soluble ST2 | |
| WO2012078502A3 (en) | Biomarker test for acute coronary syndrome | |
| Auffret et al. | Early and late ventricular arrhythmias complicating ST-segment elevation myocardial infarction | |
| Cong et al. | Predictive value of brachial-ankle artery pulse wave velocity to heart failure with preserved ejection fraction in hospitalised patients with acute dyspnoea | |
| JP2015503106A5 (enExample) | ||
| Hermany et al. | Cardiac Biomarkers in Transcatheter Aortic Valve Implantation | |
| RU2446733C1 (ru) | Способ прогноза инфаркта миокарда у больных коронарной болезнью сердца | |
| Oskouie et al. | CS as a Novel Biomarker for Diagnosis of Cardiac Allograft Rejection | |
| Berner et al. | The Assessment of Cardiovascular Risk in Patients with Acute Decompensated Heart Failure Accompanied by Chronic Kidney Disease |